Tirzepatide: The Complete Science Guide 2026 (SURMOUNT, SURPASS, SYNERGY, SURMOUNT-OSA)

Important notice: This article is intended exclusively for scientific information and research purposes. All substances mentioned are not intended for human consumption. Tirzepatide is currently not available in our shop. The current triple agonist alternative under research is Retatrutide.

Introduction: Why Tirzepatide Rewrote the GLP-1 Playbook

Tirzepatide was the molecule that turned the GLP-1 class from a diabetes drug into a full metabolic platform. Marketed as Mounjaro (T2D, FDA approval May 2022) and Zepbound (obesity, FDA approval November 2023), it was the first clinical dual agonist of GLP-1 and GIP receptors. That dual mechanism is the reason SURMOUNT-1 produced a mean weight loss of -22.5 percent at 15 mg, a number the pure GLP-1 class could not match.

Three years later, Tirzepatide has expanded into indications that no one thought possible for an appetite hormone mimetic: obstructive sleep apnoea (SURMOUNT-OSA, NEJM 2024), metabolic dysfunction-associated steatohepatitis (SYNERGY-NASH, NEJM 2024), and cardiovascular outcomes in type 2 diabetes (SURPASS-CVOT, NEJM 2025). And with SURMOUNT-5 (NEJM 2025), we finally have a head-to-head trial against Semaglutide that settles the intra-class debate.

This pillar collects the pivotal trials into one reference. All data are peer-reviewed. All PubMed IDs are verified.

Background: The Dual GLP-1/GIP Mechanism

Tirzepatide is a 39-amino-acid synthetic peptide based on the native GIP sequence, with structural modifications that give it agonist activity at both the GLP-1 receptor and the GIP receptor. C20 fatty diacid conjugation extends its half-life to roughly five days, allowing once-weekly subcutaneous dosing.

Why dual agonism matters

GLP-1 agonism drives appetite suppression through hypothalamic satiety pathways, slows gastric emptying, and enhances glucose-dependent insulin secretion. This is the mechanism shared with Semaglutide and Liraglutide.
GIP agonism appears to work additively on several fronts: it amplifies postprandial insulin response, modulates adipocyte function, and, based on preclinical data, may blunt the nausea typically seen with pure GLP-1 agonism.
The combined profile produces weight loss approximately 50 percent greater than Semaglutide at comparable doses, as later confirmed in SURMOUNT-5.

Regulatory timeline

May 2022: FDA approval as Mounjaro for type 2 diabetes
November 2023: FDA approval as Zepbound for chronic weight management
December 2024: Zepbound label expanded to include moderate-to-severe obstructive sleep apnoea
2025 onward: Ongoing outcome trials for MASH, cardiovascular disease, and chronic kidney disease

SURMOUNT-1: The Pivotal Obesity Trial

Reference: Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387(3):205-216. PMID: 35658024.

SURMOUNT-1 was the registration trial that transformed Tirzepatide from a diabetes drug into a weight-loss medication.

Design

Randomised, double-blind, placebo-controlled, 72-week Phase 3 trial
N=2,539 adults with BMI ≥30, or ≥27 with at least one weight-related comorbidity (excluding diabetes)
Four arms: placebo, Tirzepatide 5 mg, 10 mg, 15 mg subcutaneous weekly
Co-primary endpoints: percent change in body weight and proportion reaching ≥5 percent loss at Week 72

Results

Mean body weight change: -15.0 percent (5 mg), -19.5 percent (10 mg), -22.5 percent (15 mg), versus -3.1 percent on placebo
Participants achieving ≥5 percent weight loss: 85 to 91 percent (Tirzepatide) versus 35 percent (placebo)
Participants achieving ≥20 percent weight loss: 50 percent at 15 mg
Improvements across waist circumference, blood pressure, lipid levels, HbA1c, and fasting insulin

SURMOUNT-1 at a glance (PMID 35658024)

Population: n=2,539, BMI ≥30 or ≥27 with comorbidity, no diabetes
Duration: 72 weeks
15 mg arm: -22.5 percent body weight (approximately -23.6 kg from 104.8 kg baseline)
Tier response: 50 percent of patients at 15 mg lost ≥20 percent of body weight
Adverse events: Nausea (~29 percent), diarrhoea (~23 percent), mostly mild-to-moderate, early titration period
Discontinuation due to AE: 4.3 to 7.1 percent on Tirzepatide vs. 2.6 percent placebo

SURMOUNT-1 redefined what pharmacological obesity treatment looks like. A 22.5 percent loss approaches the 25 to 30 percent range typically seen only with bariatric surgery at one year.

SURMOUNT-4: Weight Maintenance and the Rebound Question

Reference: Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48. PMID: 38078870.

The classic critique of every weight-loss drug since the 1990s: what happens when you stop? SURMOUNT-4 provided the structured answer for Tirzepatide.

Design

88-week trial with a 36-week open-label lead-in phase on Tirzepatide maximum-tolerated dose (10 or 15 mg)
Participants who achieved substantial weight loss during lead-in were then randomised to continue Tirzepatide or switch to placebo for 52 weeks
N=670 at randomisation
Primary endpoint: percent change in body weight from randomisation to Week 88

Results

At randomisation (after 36-week lead-in), participants had lost a mean of 20.9 percent
Continued Tirzepatide arm: additional -5.5 percent weight loss during the 52-week maintenance period
Switched-to-placebo arm: regained +14.0 percent over the same period
Net difference: approximately 20 percent body weight gap between arms at Week 88
Participants who continued Tirzepatide maintained ≥80 percent of their lead-in weight loss; those switched to placebo kept only a fraction

The clinical implication

SURMOUNT-4 reframed obesity pharmacotherapy as chronic-disease management rather than an acute intervention. Discontinuation produces substantial weight regain on a predictable timeline, mirroring what we see when antihypertensives or statins are stopped. This finding is echoed across the entire GLP-1/GIP class.

SURMOUNT-5: Tirzepatide vs. Semaglutide Head-to-Head

Reference: Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. New England Journal of Medicine. 2025;393(1):26-36. PMID: 40353578.

For three years the intra-class question was unresolved: how much better, precisely, is Tirzepatide than Semaglutide? SURMOUNT-5 was the first randomised head-to-head trial.

Design

72-week, open-label, randomised, head-to-head Phase 3b trial
N=751 adults with obesity, without diabetes
Tirzepatide maximum tolerated dose (10 or 15 mg) vs. Semaglutide 2.4 mg
Primary endpoint: percent change in body weight from baseline at Week 72

Results

Mean weight change: Tirzepatide -20.2 percent vs. Semaglutide -13.7 percent (difference -6.5 percentage points, p<0.001)
Participants losing ≥25 percent of body weight: 31.6 percent (Tirzepatide) vs. 16.1 percent (Semaglutide)
Participants losing ≥15 percent of body weight: 64.6 percent (Tirzepatide) vs. 40.1 percent (Semaglutide)
Waist circumference reduction: -18.4 cm (Tirzepatide) vs. -13.0 cm (Semaglutide)
Adverse event profile: broadly similar; gastrointestinal events were the most common in both arms

SURMOUNT-5 - the decisive head-to-head (PMID 40353578)

First randomised head-to-head of the modern incretin era
Primary endpoint: -20.2 percent (Tirzepatide) vs. -13.7 percent (Semaglutide)
Tier response at ≥25 percent loss: nearly double on Tirzepatide (31.6 vs. 16.1 percent)
Statistical significance: p<0.001 across all weight endpoints
Tolerability: GI events dominant in both arms, comparable discontinuation profile
Clinical read: Tirzepatide offers superior weight loss at comparable safety cost; Semaglutide retains its unique cardiovascular outcome evidence from SELECT

SURMOUNT-5 does not end the debate about which drug is "better" in every clinical scenario, because the two compounds have different outcome datasets. For pure weight loss, Tirzepatide wins by a margin that is clinically meaningful, not just statistically significant.

SURMOUNT-OSA: A New Indication in Sleep Apnoea

Reference: Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. New England Journal of Medicine. 2024;391(13):1193-1205. PMID: 38912654.

Obstructive sleep apnoea (OSA) has a tight mechanistic link to obesity, but until 2024 the only approved treatments were mechanical (CPAP) or surgical. Tirzepatide became the first pharmacological therapy FDA-approved for moderate-to-severe OSA in patients with obesity (December 2024).

Design

Two 52-week parallel Phase 3 trials (SURMOUNT-OSA Trial 1 without CPAP, Trial 2 with concurrent CPAP)
N=469 combined
Primary endpoint: change in apnoea-hypopnoea index (AHI, events per hour of sleep) at Week 52

Results

Trial 1 (no CPAP): AHI change -25.3 events/hour (Tirzepatide) vs. -5.3 (placebo); difference -20.0
Trial 2 (with CPAP): AHI change -29.3 events/hour (Tirzepatide) vs. -5.5 (placebo); difference -23.8
Mean weight loss: -18.1 percent (Trial 1) and -20.1 percent (Trial 2)
Hypoxic burden, blood pressure, and high-sensitivity CRP all significantly reduced
51.5 percent of Trial 1 participants achieved OSA remission (AHI <5 or AHI 5-14 without symptoms)

Why this matters

SURMOUNT-OSA was the evidence the FDA used to expand Zepbound's label to include OSA. It is also the first demonstration that weight-driven pathophysiology, not just the obesity phenotype, responds directly to incretin therapy.

SYNERGY-NASH: Liver Fibrosis Reversal

Reference: Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. New England Journal of Medicine. 2024;391(4):299-310. PMID: 38856224.

MASH (formerly NASH) is the progressive form of metabolic liver disease and a leading cause of cirrhosis in developed countries. No drug had ever achieved MASH resolution with the consistency that SYNERGY-NASH demonstrated in 2024.

Design

52-week Phase 2 randomised, double-blind, placebo-controlled trial
N=190 adults with biopsy-confirmed MASH and stage F2 or F3 liver fibrosis
Arms: placebo, Tirzepatide 5 mg, 10 mg, 15 mg subcutaneous weekly
Co-primary endpoints: MASH resolution without worsening fibrosis; fibrosis improvement without worsening MASH

Results

MASH resolution without fibrosis worsening: 44 percent (5 mg), 56 percent (10 mg), 62 percent (15 mg) vs. 10 percent placebo (p<0.001 across all doses)
Fibrosis improvement by at least one stage without MASH worsening: 55 percent at 10 mg, 51 percent at 15 mg vs. 30 percent placebo (p<0.05)
Mean weight loss: -15.6 percent (15 mg) vs. -0.8 percent placebo
Safety profile: consistent with SURMOUNT trials; gastrointestinal events dominant

The clinical signal

A 62 percent MASH resolution rate in a population with F2-F3 fibrosis is the strongest Phase 2 signal the MASH field has seen. The Phase 3 programme (ESSENCE, separate resmetirom head-to-head trials) is ongoing. For now, SYNERGY-NASH positions the GLP-1/GIP mechanism as disease-modifying in metabolic liver disease.

SURPASS-CVOT: Cardiovascular Outcomes in Type 2 Diabetes

Reference: Del Prato S, Kahn SE, Pavo I, et al. Tirzepatide versus Dulaglutide for Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 2025. PMID: 41406444.

The final safety question for any diabetes or obesity drug remains cardiovascular. SURPASS-CVOT was the dedicated outcome trial that regulators and payers had been waiting for.

Design

Active-controlled, randomised, double-blind Phase 3 trial
N=13,299 adults with type 2 diabetes and established atherosclerotic cardiovascular disease
Tirzepatide (titrated to max tolerated) vs. Dulaglutide 1.5 mg once weekly
Primary endpoint: MACE-3 (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke)
Median follow-up: approximately 54 months

Results

MACE-3 hazard ratio: Tirzepatide non-inferior to Dulaglutide (active comparator, itself CV-protective)
Secondary outcomes: greater HbA1c reduction, greater weight loss, greater blood pressure reduction on Tirzepatide
No new safety signals; pancreatitis, thyroid C-cell tumour, and retinopathy rates comparable
Trial design means SURPASS-CVOT does not establish superiority against placebo; it establishes that Tirzepatide carries at least the same cardiovascular safety profile as an established GLP-1 analogue

Interpretation

SURPASS-CVOT is reassurance, not revelation. In an era where Dulaglutide (REWIND), Semaglutide (SUSTAIN-6, SELECT), and Liraglutide (LEADER) all demonstrated cardiovascular benefit, non-inferiority to Dulaglutide is the floor, and Tirzepatide cleared it.

2026 Context: Where the Incretin Class Is Going

Tirzepatide is still a first-in-class achievement. But the 2026 landscape has a new ceiling, and it is called Retatrutide.

TRIUMPH-4 raises the bar

Eli Lilly's triple agonist Retatrutide (GLP-1 + GIP + glucagon) reported Phase 3 TRIUMPH-4 topline results in December 2025: -28.7 percent mean body weight loss at 12 mg over 68 weeks, in patients with obesity and knee osteoarthritis. That is roughly 6 percentage points more than SURMOUNT-1's 15 mg Tirzepatide arm, with additional disease-modifying effects on knee pain (WOMAC -75.8 percent) and blood pressure (-14 mmHg systolic).

For a deeper analysis of the TRIUMPH-4 data and how it compares to SURMOUNT-1, see Retatrutide Phase 3 Update: TRIUMPH-4 Results.

The mechanistic step change

Mono-agonist (GLP-1): Semaglutide, best-in-class for pure GLP-1, ~15 percent weight loss at 2.4 mg
Dual agonist (GLP-1 + GIP): Tirzepatide, ~22.5 percent at 15 mg
Triple agonist (GLP-1 + GIP + glucagon): Retatrutide, ~28.7 percent at 12 mg (Phase 3 topline)

Glucagon agonism adds direct energy expenditure via hepatic lipolysis and thermogenesis, complementing the appetite-suppression axis rather than duplicating it. That is the reason Retatrutide achieves a step change, not just an incremental improvement.

What Tirzepatide still owns

The only dual agonist with full Phase 3 data across obesity, OSA, MASH, and cardiovascular outcomes in T2D
The only GLP-1 class member with an FDA-approved OSA indication as of 2026
The only GLP-1 class member with MASH Phase 2 data showing 62 percent resolution
Unbroken real-world experience across millions of patient-years since 2022

Retatrutide will need to replicate Tirzepatide's indication-expansion trajectory before it can claim equivalent clinical breadth. The TRIUMPH programme (TRIUMPH-1, -2, -3, -5 plus MASH, CVOT, and CKD readouts) is the roadmap.

Conclusion: Tirzepatide as the Reference Standard

Tirzepatide changed the terms of obesity and metabolic medicine. SURMOUNT-1 proved the ceiling for weight loss was not 15 percent, it was 22.5 percent. SURMOUNT-4 reframed obesity as a chronic condition. SURMOUNT-5 settled the intra-class comparison against Semaglutide. SURMOUNT-OSA, SYNERGY-NASH, and SURPASS-CVOT pushed the mechanism into indications that no one predicted from a diabetes drug.

For the research community, Tirzepatide is now the reference standard against which every next-generation candidate is measured. Retatrutide's TRIUMPH-4 readout is the first evidence that this standard can be exceeded.

The current research frontier is the triple agonist. To stay current with the Phase 3 data on Retatrutide, read our TRIUMPH-4 analysis.

Sources

Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM. 2022;387(3):205-216. PMID: 35658024.
Aronne LJ, Sattar N, Horn DB, et al. SURMOUNT-4: Continued Treatment With Tirzepatide for Maintenance of Weight Reduction. JAMA. 2024;331(1):38-48. PMID: 38078870.
Aronne LJ, Horn DB, le Roux CW, et al. SURMOUNT-5: Tirzepatide as Compared with Semaglutide for Obesity. NEJM. 2025;393(1):26-36. PMID: 40353578.
Malhotra A, Grunstein RR, Fietze I, et al. SURMOUNT-OSA: Tirzepatide for OSA and Obesity. NEJM. 2024;391(13):1193-1205. PMID: 38912654.
Loomba R, Hartman ML, Lawitz EJ, et al. SYNERGY-NASH: Tirzepatide for MASH with Fibrosis. NEJM. 2024;391(4):299-310. PMID: 38856224.
Del Prato S, Kahn SE, Pavo I, et al. SURPASS-CVOT: Tirzepatide vs. Dulaglutide for CV Outcomes in T2D. NEJM. 2025. PMID: 41406444.
Eli Lilly and Company. TRIUMPH-4 topline press release. December 2025.